Sage Journals: Discover world-class research

Abstract

Serotonin syndrome is thought to arise from serotonin excess. In many cases, symptoms are mild and self-limiting. But serotonin syndrome can become life threatening, when neuromuscular hyperexcitability spins out of control. Uncontainable neuromuscular hyperexcitability may lead to cardiovascular complications, linked to extreme changes in blood pressure. Currently, there is little guidance on how to control blood pressure in hyperserotonergic states. We report a case with treatment-resistant arterial hypertension, followed by a clinical review (using systematic review principles and techniques) of the available evidence from case reports published between 2004 and 2016 to identify measures to control arterial hypertension associated with serotonin syndrome. We conclude that classic antihypertensives may not be effective for the treatment of severe hypertension associated with serotonin syndrome. Benzodiazepines may lower blood pressure. Patients with severe hypertension not responding to benzodiazepines may benefit from cyproheptadine, propofol or both. In severe cases, higher cyproheptadine doses than currently recommended may be necessary.

Keywords

antihypertensive agents arterial hypertension cyproheptadine hypertension propofol serotonin antagonists serotonin syndrome

Introduction

Awareness of serotonin syndrome (SS) as a severe form of serotonin toxicity has increased. Yet, it remains a diagnostic challenge in everyday practice. SS is thought to arise from 5HT_1A and 5HT₂ receptor stimulation, resulting in neuromuscular hyperexcitability. SS has been linked to a variety of drugs with direct or indirect serotonergic actions (Table 1).^1–4 The risk of SS increases with the use of serotonergic agents in escalating doses, or combination of two or more serotonergic agents. The risk of SS also increases with the concomitant use of other agents reducing the metabolism of serotonergic agents, or hepatic or renal impairment.^4,5 In many cases, symptoms are mild and self-limiting. But if not recognized in good time, neuromuscular hyperexcitability can spin out of control. Then, SS can become life threatening. Uncontainable neuromuscular hyperexcitability may ensue in cardiovascular complications. Such are linked to extreme changes in blood pressure (BP). Currently, there is little guidance on how to control BP in hyperserotonergic states. We report a case of SS with treatment-resistant hypertension as the lead symptom. We then present a clinical review of the literature to identify measures to control arterial hypertension associated with SS.

Table 1.

Agents associated with an increased risk of serotonin syndrome.

Monoaminoxidase (MAO) inhibition

MAOI antidepressants
Linezolid
Methylene blue
MAO B inhibitors

Serotonin-reuptake inhibition

SSRIs
SNRIs antidepressants or other SNRI agents such as atomoxetine or sibutramine
TCAs
Bupropion (indirect effect)
Some opioids such as tramadol, pethidine (meperidine), pentazocine or dextromethorphan
Metoclopramide
Setrones
Valproate
Carbamazepine
MDMA (‘Ecstasy’)^*

Serotonin release

Amphetamines and amphetamine derivatives including central stimulants and fenfluramine or recreational stimulants
Levodopa, carbidopa–levodopa (indirect effect)

Other/unspecified mechanisms leading to increased serotonin activity

Fentanyl
Lithium
Buspirone
Ergotamine
LSD

Complementary medicines/dietary supplements with serotonergic activity

Tryptophan
Panax ginseng
St John’s wort (Hypericum perforatum)
SAMe

Unclear/debated whether associated with increased risk

Triptans
Mirtazapine
5HT2-blocking antipsychotics

Also promotes serotonin release.

5HT, 5-hydroxytryptamine; LSD, lysergic acid diethylamide; MAOI, monoaminoxidase inhibitors; MDMA, 3,4-methylenedioxymethamphetamine; SNRI, serotonin–noradrenaline-reuptake inhibitor; SSRI, selective serotonin-reuptake inhibitor; TCA, tricyclic antidepressant.

Case report

A 73 year-old White woman was admitted to the emergency department with a 4-week history of cough and nausea and a 1-week history of dyspnoea. At 8 days prior to admission, she had been started on erythromycin because of pulmonary crackles suggestive of a chest infection. Feeling worse, she stopped erythromycin after 6 days.

She had a prior history of arterial hypertension and mild coronary heart disease treated with furosemide and acetylsalicylic acid. She was treated with a combination of 15 mg escitalopram and 225 mg venlafaxine for a chronic depression, which had not responded to monotherapy alone. Escitalopram had been increased to its current dose 3 months ago.

At admission, she presented fully orientated with pallor, tachypnoea (24 bpm) and bilateral crackles. There was no oedema. The initial BP was 130/60 mmHg, rising to 170/66 mmHg after 40 min. The temperature was 36.1°C and oxygen saturation 100% with 3 l O₂ via nasal cannula. The patient’s previous electrocardiography (ECG) had been normal. Now, the ECG showed sinus rhythm (100 bpm) with episodes of fast atrial fibrillation at 160/min and short bursts of ventricular tachycardia, both self-limiting. The ECG showed deep anterolateral and inferior ST-depressions. The patient was immediately transferred for catheterization, which showed an old occlusion of the right cardiac artery. At 14 months prior to the current episode, creatinine was normal with 70 µmol/l. At 5 months prior to the current episode, the venlafaxine concentration was 698 nmol/l, well within the therapeutic range of 90–900 nmol/l. Now, the laboratory results showed a severe hyperkalaemia in the context of renal failure (for complete laboratory results, see Table A1).

The patient received calcium, sodium bicarbonate and glucose–insulin to treat the hyperkalaemia. She was transferred to the intensive care unit. At 10 min after the initiation of haemodialysis without ultrafiltration, the BP fell to 60/35 mmHg. The patient stabilized quickly but stayed anuric thereafter. The abdominal computed tomography (CT) was normal.

Further into the dialysis, the patient became increasingly agitated. Her BP rose to 240/110 mmHg. She developed atrial fibrillation, which responded to 4 mg intravenous (i.v.) metoprolol. However, the BP remained high. The patient then decreased in consciousness and scored 7/15 on the Glasgow Coma Scale (GCS). She developed muscular rigidity with hyperreflexia, inducible clonus and upgoing plantars. She also had mydriasis despite morphine administration and slow, pendular, horizontal (roving) eye movements. A cranial CT was normal. As her hypertension did not improve and the neurological abnormalities persisted without any apparent cause, we reconsidered our differential diagnosis. Re-review of the patient’s drug chart alerted us to the fact that she was treated with two serotonergic antidepressants and had recently been exposed to erythromycin, which might have interfered with the metabolism of her antidepressants. Neither prior to admission nor during her hospital stay had the patient received any other serotonergic agents, such as serotonergic opioids. Apart from erythromycin, the patient had not either received any other agent that could have interacted with her antidepressants pharmacologically.

As the symptoms fulfilled all three diagnostic criteria systems, SS was diagnosed. At this point, the patient had a constant BP around 220/85 not responding to any conventional treatment (Table 2) or benzodiazepines. Cyproheptadine was started. After administration of 12 mg, the BP began to decrease and finally fell to 150/65 after 4 h. At the same time, the patient improved neurologically and achieved 14/15 points on the GCS. The BP started to increase again 11 h later despite maintenance with 2 mg cyproheptadine every 2 h. However, the BP could now be contained with amlodipine and metoprolol. After 24 h, cyproheptadine was stopped.

Table 2.

Antihypertensive treatment in our case.

Substance	Dose	Cumulative dose/treatment time	Route	Effect
Treatment before start of cyproheptadine (6 h)
Glyceryltrinitrate	0.2–0.5 µg/kg/min	120 min	i.v.	Only transient decrease in BP despite increasing doses
Clonidine	150 mg	300 mg	i.v.	None
Labetolol	10 mg bolus, then 25–50 mg/h	50 mg over 150 min	i.v.	None
Metoprolol	1–2.5 mg	25 mg	i.v.	Satisfactory on tachycardia, none on BP
Furosemide	Variable	1240 mg/6 h	i.v.	Persistent anuria
Midazolam	1–4 mg/h	18.8 mg over 6 h	i.v.	Less rigidity and agitation. No effect on BP
Diazepam	10 mg		i.v.
Morphine	2.5 mg	2.5 mg	i.v.	None
Cyproheptadine treatment (8 h)
Cyproheptadine	12 mg initially, then 2 mg every 120 min for 8 h	16 mg/8 h	p.s.	BP decrease from 205/85 to 150/65 in 4 h, sustained for more than 8 h
Treatment during cyproheptadine maintenance (12 h)
Cyproheptadine	2 mg every 4 h for 12 h	6 mg/12 h	p.s.	Rising BP, controlled with systolic readings between 170 and 200 mmHg with combined treatment
Amlodipine	5 mg	15 mg	p.s.
Metoprolol	1–2.5 mg	30 mg	i.v.
Midazolam	1–15 mg	19 mg	i.v.
Treatment after cyproheptadine discontinuation (3 h)
Metoprolol	1–2.5 mg	3.5 mg	i.v.	Rising BP to over 200 mmHg despite treatment
Clonidine	75 mg	150 mg	i.v.
Labetolol	5–10 mg	35 mg	i.v.
Minoxidil	2.5 mg	5 mg	p.s.
Addition of cyproheptadine in maintenance dosage (2 h)
Cyproheptadine	2 mg	4 mg	p.s.	no improvement
Propofol treatment (10 h)
Propofol	Initially 40 mg, then 20 mg	40 min	i.v.	Fast decrease from 210/75 to 160/70, reaching 135/60 after 5 h
	1–4 ml/h	10 h	i.v.
Treatment after propofol discontinuation
Bisoprolol	5–7.5 mg	25 mg/d	p.o.	Controlled between 130/50–180/70
Doxazosin	4 mg	4 mg/d	p.o.
Amlodipine	5 mg	15 mg/d	p.o.
Diazepam	10 mg	30 mg/d	p.o.

BP measurements in mmHg.

BP, blood pressure; i.v., intravenously; p.s., via nasogastric tube; p.o., orally.

Around 12 h later, after discontinuation of cyproheptadine, high BP and neurological symptoms recurred despite continued treatment with midazolam, amlodipine and metoprolol. Neither clonidine, labetalol, minoxidil, nor reinstitution of cyproheptadine in maintenance dose had effect on BP. Finally, propofol was initiated, leading to a rapid improvement of both BP and neuromuscular symptoms. After 10 h, propofol was discontinued. The patient was then able to swallow. BP was successfully contained with amlodipine, doxazosin, bisoprolol and diazepam. She also received ECG monitoring for a suspected type 2 myocardial infarction for another 48 h. However, 4 days after her initial presentation to the emergency department, she developed ventricular fibrillation unresponsive to resuscitation and asystole. The post-mortem examination revealed a myocardial infarction and a myeloma kidney. No post-mortem CYP genotyping was performed.

The Ethical Review Board in Umeå declared that according to the Swedish Ethical Review Act, this study of a deceased person was not in need of an ethical review board approval. The Ethical Review Board declared further that it did not see any research ethical problems with the case report. The husband of the deceased person had given his verbal informed consent to publication, which was documented in the deceased patient’s case notes at the time.

Literature review

We conducted a clinical review, using systematic review principles and techniques, of interventional and observational studies on the effect and outcome of BP-lowering treatment in SS.

Search strategy

We searched MEDLINE, ISI Web of Science: Science Citation Index Expanded, Cochrane Central Register of Controlled Trials CENTRAL, the Cochrane Library, CINAHL, TOXNET Toxline search and ClinicalTrials.gov. We used the following search terms: ‘serotonin syndrome’ OR ‘serotonin toxicity’ and ‘hypertension’ OR ‘hypertensive’. As this review did not identify any relevant studies, we proceeded to searching cases reporting on treatment of hypertension in SS. For this, we screened two databases that contained case reports, MEDLINE(R) and ISI Web of Science. We searched for articles published between 1 January 2004 and 31 December 2016 for articles containing the terms ‘serotonin syndrome’ or ‘serotonin toxicity’. We assessed all case presentations concerning patients over 18 years fulfilling the criteria for SS according to at least one of the three available classification systems (Sternbach, Radomski et al. or Hunter Serotonin Toxicity Criteria).^6–8 We chose the year 2004 as a cut-off point, because by that time, all three classification systems were available (Table A2 and A3).

Inclusion criteria

We considered all cases meeting the definition of at least one of the three available diagnostic systems. In all cases, after differential diagnostic consideration, SS emerged as the most likely diagnosis. Two investigators independently double rated all cases regarding the three diagnostic systems. This method has been reported in detail elsewhere.⁴ We screened these case reports for information regarding BP and antihypertensive treatment. We included all cases that reported severe hypertension, defined as a systolic BP of 175 mmHg or more, measured in an acute setting.

Exclusion criteria

We excluded all cases (a) not meeting any of the diagnostic criteria despite claiming a diagnosis of SS; (b) being aetiologically uncertain despite meeting the diagnostic criteria; (c) containing insufficient clinical information to rate; (d) being historical; or (e) implicating use of first-generation antipsychotics or concomitant neuroleptic malignant syndrome.

Data extraction

We abstracted all eligible cases into a new dataset, including general patient characteristics, onset, clinical course, mode of presentation, symptoms, diagnostic criteria, associated medications, treatment and outcome. All cases were summarised according to two criteria: (a) type of hypertensive treatment; and (b) type of response. Type of response was further stratified into (a) therapeutic response within less than a day (rapid); or (b) therapeutic response after 24 h or no response at all (slow or no).

Results

The systematic search of the literature yielded 403 articles with 493 potentially eligible cases. Of these, 119 were excluded so that 374 cases remained (Appendix 4). Of these, 49 cases reported severe arterial hypertension of at least 175 mmHg systolic and 22 commented on the antihypertensive treatment and outcome (Table 3).^9–29

Table 3.

Treatment of high blood pressure (>175 mmHg) in serotonin syndrome as reported in the literature 2004–2016.

Case	Highest BP	Substance	Dosage	Effect
Rapid therapeutic response (⩽ 24h)
1. Gnanadesigan et al.¹⁴	200/90	Lorazepam	i.v., dose n.s.	In less than a day BP returned to baseline
2. Monterrubio Villar and Cordoba Lopez²³	220/100	DiazepamNitroglycerine	n.s.Several puffs	Rapidly controlled
3. Ozkardesler et al.²⁵	200/114	Morphine Diphenhydramine Dexamethasone	1 mg × 3 i.v.20 mg i.v.8 mg i.v.	135/90 after 2 h
4. Monte and Waksman²²	177/80	PropofolClorazepateLorazepam	30 mg × 530 mg p.o.24 mg i.v.	No effect of clorazepate and lorazepam; after propofol, normalization in 45 min
5. Monte et al.²¹	177/113	Lorazepam	Repetitive doses i.v.	Normal after 6 h
6. Rim and Gitlin²⁶	180/100	Lorazepam	12 mg in two doses i.v.	Rapidly improved
7. Choudhury et al.¹³	200/100	NitroglycerineDiazepamCyproheptadine	1 µg/kg/min5 mg i.v.20 mg p.o.	Effect of nitroglycerine not disclosed, but improvement 4 h after diazepam/cyproheptadine; resolution after 30 h
8. Levine et al.¹⁸	249/145	Diltiazem	20 mg i.v. over 5 min.	BP decreased to 66/54 after 15 min; persistent hypotension, needed norepinephrine
9. Miller and Lovell²⁰	234/196	Propofol Lorazepam	Continuous i.v.Multiple doses i.v.	150/85 (after intubation)
10. Gollapudy et al.¹⁵	180/80	FentanylHydromorphone	100 µg0.4 mg	Unresponsiveness and apnoea leading to intubation; BP 99/58 after 1 h
11. Wilson et al.³⁰	Fluctuating between 180 and 90 systolic	Benzodiazepines Cyproheptadine	n.s.n.s.	Benzodiazepines without effect. 2 h after cyproheptadine BP swings less pronounced and finally stabilized
12. Beatty et al.⁹	200 systolic	MidazolamEsmololFentanylLorazepam Hydromorphone	2 mg over 5 min50 mg over 15 min50 µg × 21 mg0.4 mg + 1 mg i.v. over 90 min	Hyperdynamic after esmolol; clinically worse after fentanyl; BP normal 2 h after monotherapy with hydromorphone
13. Ma et al.¹⁹	180/100	MidazolamPropofol	5 mg/hn.s.	No control of symptoms until propofol added
14. Moseson et al.²⁴	Fluctuating BP with MAP 40, then systolic BP in the 200s and MAP >100	MetoprololNicardipineCyproheptadineBenzodiazepines	10 mg i.v. initiallyi.v. drip initiallyOne dosen.s.	MAP dropped again to 40 after metoprolol/nicardipine; needed epinephrine; normalization 24 h after cyproheptadine
15. Shah and Jain³¹	230/120	CyproheptadineMidazolam	12 mg, followed by 2 mg every 2 hcontinuously	8 h after cyproheptadine; BP returned to normal
Slow or no therapeutic response (⩾24 h)
16. Brown¹²	177/111	LorazepamDiphenhydramine	1 mg every 6 h25 mg every 6 h	Decreased, but never resolved over 6 days; after 6 days of treatment effect of nitroglycerin on a BP of 159/105
17. Velez et al.²⁷	188/103	LorazepamCyproheptadine	30 mg i.v. over 6 h8 mg p.t., then 3 × 4 mg/24 h	No improvement; fluctuating BP over 2 days (112–211 systolic)
18. Bergeron et al.¹⁰	206/102	BisoprololMethotrimeprazineOlanzapineOndansetron	5 mg daily25 mg daily12.5 mg daily8 mg daily	On day 5 BP between 160/80 and 138/80
19. Inoue et al.¹⁶	202/86	Nicardipine	1.7 µg/kg/min in decreasing dose over 10 days	Gradual decrease in BP over 2 weeks
20. Isenberg et al.¹⁷	210/93	LorazepamMidazolamDiphenhydramineHydromorphoneCyproheptadine	8 mg in four doses4 mgn.s.2 mg i.v.4 mg p.t.	No change with any treatment before cyproheptadine; effect of cyproheptadine on BP not reported
21. Young et al.²⁹	210/120	Nitroglycerine	i.v.	No satisfying control of BP
22. Bosak et al.¹¹	230/104	MidazolamLorazepam DiazepamPhenobarbital PropofolCyproheptadineFentanyl	Various dosagesVarious dosagesInitially 15 mg/kg, then n.s.60–80 µg/kg/min12 mg p.t.175 µg/h	Badly controlled for 96 h under continuous fentanyl treatment with repetitive hypertensive episodes while sedation was weaned

BP measurements in mmHg.

BP, blood pressure; i.v., intravenously; MAP, mean arterial pressure; n.s., not specified; p.o., orally; p.t., via gastric tube.

Sixteen patients received benzodiazepines. As monotherapy, this led to a relevant reduction of BP in three cases (cases 1, 5, 6). Combination therapy decreased BP in a further three cases (cases 2, 7, 9). ‘Classical’ antihypertensive agents included calcium antagonists, nitrates and beta blockers. Of these, only diltiazem, used in monotherapy, took effect. In the respective case (case 8), however, diltiazem, led to severe hypotension. Hydromorphone was effective in two cases (cases 10, 12). In case 10, hydromorphone was used in combination with fentanyl. This combination led to apnoea. Propofol was used in four cases. It was clearly effective in two cases (case 4, 13), and in another case (case 9), when used in combination with lorazepam. Cyproheptadine was used in seven cases. It proved effective as a single agent in two cases (case 11, 15) and as combination treatment in two further cases (case 7, 14) (Table 4).

Table 4.

Effect of antihypertensive agents, number of cases.^#

Substance	Effect clearly demonstrated as single agent	Effect in combination with other agents	Slow or lacking effect
Benzodiazepines
Lorazepam	3	1	4
Diazepam		2	2
Midazolam		1	5
Clorazepate			1
Unspecified			1
Ca ²⁺ antagonists
Diltiazem	1^*
Nicardipine		1^*	1
Amlodipine		1^‡
Opiates
Hydromorphone	1	1^§	1
Morphine		1	1
Fentanyl		1^§	2
Nitrates
Nitroglycerine		1	1
Glyceryltrinitrate			1
β-, α- or α+β-receptor blocker,
Metoprolol		1^*	1
Bisoprolol		1^‡	1
Esmolol			1
Doxazosin		1^‡
Labetalol			1
Central antihypertensive agents
Clonidine			1
K-channel opener
Minoxidil			1
Anaesthetics
Propofol	3	1	1
Phenobarbital			1
Antihistaminic agents with antiserotonergic properties
Cyproheptadine	3	2	3
Diphenhydramine		1	2
Agents with 5-HT2a or 5HT3 antagonist activity
Olanzapine			1
Methotrimeprazine			1
5-HT3 antagonist
Ondansetron			1
Glucocorticosteroids
Dexamethasone		1

Including our case.

Followed by severe arterial hypotension.

‡

In combination with cyproheptadine.

Apnoea (combination hydromorphone with fentanyl).

Discussion

Severe SS is often the result of a chain of events leading to a catastrophic outcome. It is well known that SS can precipitate autonomic instability and BP changes. But clinicians may not be aware that SS may be associated with severe hypertension that resists treatment with conventional antihypertensive therapies.

Reconstructing the likely catastrophic chain of events: our case

In our case, we established ventricular fibrillation with cardiac arrest as the immediate cause of death, secondary to a type 2 myocardial infarction. This myocardial infarction was most likely an aftermath of an 8 h episode of severe hypertension in the context of a SS.

Until the event, this patient had successfully and uneventfully been maintained on the combination of two antidepressants over a period of 9 months.

Potential role of hepatic CYP inhibition

In our case, the SS may have been precipitated through addition of erythromycin, which is a CYP3A4 inhibitor.

Venlafaxine is metabolized by several hepatic microsomal enzymes. CYP2D6 metabolizes venlafaxine to O-desmethylvenlafaxine, an active metabolite. CYP2C19 and CYP3A4 facilitate N-demethylation (a) of venlafaxine to the inactive metabolite N-desmethylvenlafaxine and (b) of O-desmethylvenlafaxine to the clinically insignificant metabolite N,O-desmethylvenlafaxine.^32,33 When adding erythromycin as a CYP3A4 inhibitor, the levels of the various agents will change. The net result will depend on patient’s CYP2D6/2C19 genotypes. However, most likely, inhibition of CYP3A4 will lead to higher levels of venlafaxine and O-desmethylvenlafaxine.

Escitalopram is metabolized to the active metabolite S-desmethylcitalopram by CYP2C19 and to a lesser degree by CYP2D6 and CYP3A4. S-desmethylcitalopram is further metabolized by CYP2D6 to S-didesmethylcitalopram, which is also pharmacologically active.^33,34 Erythromycin can also increase levels of escitalopram. This will depend on CYP2C19 genotype. If CYP2C19 activity is reduced, CYP3A4 becomes important.

We have identified three further case reports of SS in the context of macrolide antibiotics in combination with selective serotonin-reuptake inhibitors (SSRIs). The first case concerned a combination of paroxetine and clarithromycin in a 36-year-old woman,³⁵ the second sertraline and erythromycin in a 12-year-old boy,³⁶ and the third case fluoxetine and clarithromycin in a 53-year-old man.³⁷

The individual risk of developing SS will partly depend on gene polymorphisms that increase serotonin sensitivity. In our case, the patient’s CYP2C19 and CYP2D6 genotypes would have been of great interest, but no post-mortem genotype testing was performed. Gene polymorphisms can vary considerably, for instance, according to ethnicity. They may affect pharmacokinetic factors, such as the CYP system. They may also affect pharmacodynamic mechanisms, such as serotonin signal transduction via the 5HT₂ receptor.³⁸

We also considered whether the underlying infection could have changed the permeability of our patient’s blood–brain barrier. However, this is unlikely because the patient had a chest and not a central nervous system infection. We also considered the likelihood of arrhythmia caused by erythromycin. However, erythromycin has a short half-life and the patient had discontinued erythromycin 2 days prior to admission.

Potential role of renal impairment

In our case, renal failure has most likely also contributed to the development of SS; 92% of venlafaxine and its metabolites are renally eliminated.³² Around 8–10% of escitalopram is excreted renally unchanged.³⁴ We do not know when the patient had developed multiple myeloma kidneys. As the decline of renal function was not detected, escitalopram and venlafaxine were not adjusted and may have increased in plasma concentration.

Hypertension as a consequence of serotonin toxicity

In therapeutic doses, venlafaxine, a serotonin and noradrenaline reuptake inhibitor (SNRI), raises BP very modestly.³⁹ Hypertensive crisis in overdose has been described.⁴⁰ In that case, which did not have features of SS, BP responded to labetalol, a beta blocker with antinoradrenergic properties. In our case, treatment with labetalol did not show any effect, whereas cyproheptadine led to dramatic improvement. This suggests that the arterial hypertension was a consequence of serotonin toxicity rather than a hyperadrenergic state.

Understanding hypertension in the context of serotonin toxicity

Neuromuscular symptoms and hypertension may not lie on a continuum, and only a minority of patients with SS develops hypertension.⁷ It is unclear why serotonin toxicity can precipitate a hypertensive crisis. Serotonin plays a crucial role in cardiovascular regulation. Serotonin exerts effects on BP by a multitude of mechanisms. In the peripheral circulatory system, serotonin binds to 5-HT receptors in the blood vessels. Here, it causes predominantly direct arterial constriction. Under certain conditions, serotonin can even have vasodilatory effects. In the heart, serotonin has been shown to increase inotropy. It is also arrhythmogenic. Serotonin influences the sympathetic nervous system, both peripherally and centrally. Dependent on which receptor is activated, serotonin can either lower or raise BP and effects vary over time.^41–43 In patients with renal insufficiency, free plasma serotonin accumulates and is not eliminated by dialysis.⁴⁴ Since serotonin does not cross the blood–brain barrier, central neurologic signs of SS cannot be explained by impaired renal excretion. However, the proportion of central and peripheral effects of serotonin on BP in our patient will remain unresolved.

One other setting that links serotonin to hypertension is pulmonary hypertension of the newborn (PPHN) associated with SSRI use in the second half of pregnancy. The mechanism behind this adverse SSRI effect remains unclear. Serotonin is a potent pulmonary vasoconstrictor, and the serotonin transporter is involved in the pulmonary artery smooth muscle proliferation.^45,46 One study has shown that SSRI caused ductus arteriosus constriction and made vessels less sensitive to prostaglandin-induced vasodilatation.⁴⁷ Prostaglandin E2 agonists are potent vasodilators. Yet, to our knowledge, they have never been used in the treatment SS-associated hypertension.

Treating hypertension in the context of SS: lessons from our case report analysis

SS can occur in a variety of clinical settings. As each case is different, tailoring the treatment to the underlying pathophysiology is not easy. Hence, it comes as no surprise that experts do not agree. Boyer and Shannon have recommended nitroprusside and esmolol.^1,5 Others have suggested propranolol or cyproheptadine.⁷ All agents used in the treatment of SS are used off label.

Beta blocker and combined beta and alpha blocker (labetalol) had no effect on the BP in our case. Another case in our review also reported a lack of effect (case 18). One patient became even hyperdynamic after esmolol (case 12). In our patient, conventional antihypertensive agents only yielded a response effect after administration of the serotonin antagonist cyproheptadine and (later in the course) propofol. Only then, metoprolol, co-administered with amlodipine, and bisoprolol, co-administered with amlodipine and doxazosin, took effect.

Calcium antagonists (calcium-channel blockers, CCBs) interact with serotonin-induced vascular contraction via pharmacologic overlap between L-type calcium- and 5-HT receptors.⁴⁸ In one case, the nondihydropyridine-CCB diltiazem had fast effect on BP (case 8). This led to prolonged hypotension, necessitating norepinephrine. Treatment with nicardipine, a dihydropyridine-CCB, did not lower BP substantially in a second case (case 19). A third case (case 14) with autonomic instability was difficult to rate. In that case, the patient was hypotensive both before and after the treatment with nicardipine, given in combination with metoprolol. Nondihydropyridine-CCBs may be superior to dihydropyridine-CCBs in hyperserotonergic states. Possibly, nondihydropyridine-CCBs inhibit serotonin-induced vasoconstriction.⁴⁹ This may be a 5-HT2-receptor-mediated effect.⁵⁰ At higher serotonin doses, though, oral diltiazem lacked effect on radial arteries.⁵¹

The use of central antihypertensive drugs in SS has not been previously described. The central alpha₂-agonist clonidine affects serotoninergic neurons and decreases serotonin levels in the medulla oblongata.⁵² But in our case, clonidine lacked effect on BP.

Nitroglycerine provides nitric oxide to induce vasodilatation via generation of cyclic guanosine monophosphate (GMP). This activates calcium-sensitive potassium channels in the cell membrane. Nitroglycerin proved effective in a case with hypertension (case 2), but ineffective in a second (case 21). A third case is difficult to rate since nitroglycerine was given very late in the clinical course at a lower BP (case 16). In our patient, we did not see any effect on BP despite escalating intravenous doses. Data on nitroglycerine remains limited, and no data are available on nitroprusside. As sublingual nitrate is widely available, it may be worth a try.

Benzodiazepines have direct vascular vasodilatory effects on both arteries and veins. It has been hypothesized that the reduction of peripheral vascular resistance is a consequence of decreased catecholamine levels. Binding to central gamma-amino butyric acid receptor would lead then to decreased adrenergic amine production. In addition, benzodiazepines can peripherally depress the baroreceptor reflex.^53–56

Cyproheptadine is an antihistamine with anticholinergic and antiserotonergic properties. It has antagonistic effects on several serotonin receptors including 5-HT1_A,D, 2_A,B,C, 3, 6 and 7.⁵⁷ Cyproheptadine has been used to treat hyperserotonergic states in carcinoid syndrome.⁵⁸ Today, cyproheptadine is the antidote of choice for moderate SS.⁵⁹ It is only available in oral form and quickly resorbed.⁶⁰ Positron emission tomography (PET) scan studies in two healthy men show a blockade of 85% and 95% of 5-HT2 receptors in the prefrontal cortex, respectively, with 12 mg and 18 mg daily over 6 days.⁶¹ In SS, an initial dose of 12 mg is recommended, followed by 2 mg every 2 h to a maximum of 32 mg in 24 h until symptoms settle.⁶² This dose was insufficient in our case. Our patient showed a good initial response but relapsed after 8–11 h under maintenance with 2 mg every 2 h. While the effect faded, we were able to control the BP with CCB and beta blocker. Once cyproheptadine was stopped, this regimen did not work any longer.

In our review, we identified seven cases with hypertension treated with cyproheptadine (cases 7, 11, 14, 15, 17, 20, 22). Two cases describe a quick effect within hours (cases 7 and 11). Case 14 observed reversal of the autonomic instability. Case 17 did not see any improvement, using 8 mg cyproheptadine initially followed by three 4 mg doses. Equally, case 22 must be regarded as a treatment failure. Here, normalization of the high BP took 96 h. But this patient was continuously treated with fentanyl at the same time. Fentanyl may cause SS in its own right and may have maintained the hypertension that way.

Cyproheptadine has been used in higher doses in maintenance therapy outside the SS arena: in carcinoid syndrome, up to 48 mg daily has been used.⁶³ In adults, 0.5 mg/kg is considered the maximal daily dose for treatment of hypercortisolism or allergy.⁶⁰ Toxicity for single doses is believed to lie beyond 250 mg⁶⁴ or 3 mg/kg.⁶⁰ Thus, there is scope to give higher doses than 32 mg daily if the clinical course develops unsatisfactorily.

Propofol has been established as a possible treatment in SS, mostly due to its effect on the neuromuscular symptoms. Propofol inhibits 5HT3-receptors at supratherapeutic concentrations.⁶⁵ Direct effects of propofol on 5-HT1 or 5-HT2 receptors have not been studied. Propofol antagonizes serotonin-induced arterial contraction,⁶⁶ either as a direct effect on 5-HT receptors or via inhibitory effects on platelet aggregation.⁶⁷ Probably, propofol reduces systemic vascular resistance.⁶⁸ The antihypertensive effect of propofol is well known to anaesthetists.

In three of the four available cases, propofol was effective (cases 5, 9, 13). The case not responding to therapy was the one on continuous fentanyl (case 22). In our patient, we saw an immediate drop of BP, leading to normal BP after 5 h. If the antihypertensive effect of propofol was mediated through 5-HT receptors, propofol could retain its antihypertensive properties in hyperserotonergic states. This would make propofol the antihypertensive drug of choice in SS for patients in need of intensive care.

Preventing severe serotonin syndrome

Choosing and dosing serotonergic drugs

Ultimately, the risk of SS should be minimized whenever possible. Preventive measures include combining multiple serotonergic agents only if absolutely necessary and avoiding dose escalation. It is also important to remain alert of pharmacokinetic factors that could increase plasma concentrations, such drug–drug or gene–drug interactions.

In our case, an SNRI (venlafaxine) and an SSRI (escitalopram) were used in combination for a chronic depression, which had not responded to monotherapy alone. Here, the question arises, whether this combination of venlafaxine and escitalopram is an appropriate augmentation strategy. The medical records suggest that the patient was difficult to treat and had not responded to a combination of venlafaxine and mianserin. Presumably, because mianserin is structurally similar, mirtazapine augmentation was not attempted. It remains unclear why the combination of SSRI and SNRI was preferred over other augmentation strategies apart from mirtazapine. Pharmacologically, the combination of venlafaxine and escitalopram offers little advantage. Venlafaxine, like escitalopram, has predominantly serotonergic properties.⁶⁹ Thus, the therapeutic gain may be small. Yet, pharmacology does not always predict treatment response.⁷⁰ Gonul and colleagues reported four cases, in whom an SSRI brought additional effect to venlafaxine.⁷¹ This combination carries a risk of SS. In a meta-analysis of 299 cases of SS published since 2004,⁴ we found nine cases, in which venlafaxine and SSRIs had been combined or where a swap had occurred in close temporal relation. In seven of these cases, however, there were also other serotonergic agents present. Whereas, clinicians need to remain flexible in their approach to treatment-refractory combinations,⁷⁰ they need to inform patients of the risk of SS when combining two serotonergic agents. Moreover, they should alert patients to the fact that not only medicines used for depression, but also some medicines used for physical health problems, can increase risk of SS.

Patients treated with serotonergic drug combinations should be monitored regularly to pick up signs of serotonin toxicity early. Serotonin toxicity lies on a continuum from mild to severe. Symptoms are variable (Table A2). Mild cases may only present with restlessness (akathisia) with or without tremor. Severe cases may present with high temperatures and rigidity (hypertonicity).⁵ Rigidity in its own right can mask other symptoms of neuromuscular hyperactivity, such as tremor and hyperreflexia. Even for severe cases, symptoms are variable and nonspecific. In our meta-analysis, we found that only 75% of SS cases requiring intensive care presented with fever, defined as a temperature >38°C (100.4°F). Only 18% of cases presented with hyperthermia, defined as a temperature >41.1°C (106.0°F).⁴

Strengths of our review

To our knowledge, this the first review to use systematic review principles and techniques to assess SS-associated severe hypertension and its treatment. All included cases were validated by two reviewers to ensure all cases met at least one diagnostic criteria system. We identified and analysed all published cases, following techniques as outlined in the PRISMA guidelines for systematic reviews. By integrating our own case with all other cases identified from the literature we hope to maximize the utility of our review for clinicians working in emergency scenarios. Acute threat to life demands quick decisions that are not reversible.

Limitations of our review

Only little evidence is available regarding the management of severe hypertension in the context of SS. As we could not identify any trial or observational study, we had to resort to individual case reports. Such anecdotal observations can be used as a starting point to explore this clinical problem of potentially life-threatening dimensions. Ignoring case reports due to methodological concerns such as selection bias is not an option where clinical evidence is virtually absent and clinical guidance relies mainly on expert opinions.⁴ Uncommon or emerging clinical phenomena rely on pattern recognition of cases. Applying systematic review techniques to the present analysis is a robust way to collate and analyse anecdotal, but important, clinical information.

Conclusion

Severe arterial hypertension due to SS is a life-threatening condition. SS occurs in a multitude of settings and disguises. The therapeutic approach has to take individual comorbidities into consideration. Some classic antihypertensives may not be effective. The vast majority of patients are initially treated with benzodiazepines targeted at neuromuscular symptoms.

Based on the limited evidence available, we conclude that patients with severe hypertension not responding on benzodiazepines may benefit from cyproheptadine with or without propofol with the shortest delay possible to prevent serious cardiovascular damage. Both substances may even improve the neuromuscular symptoms. Since propofol is given i.v., the dosage can be easily titrated. Current dosing recommendations for cyproheptadine may be too low in severe cases. Maintenance of antiserotoninergic treatment may be necessary for periods of several days.

Supplemental Material

Appendix_1_Diagnostic_criteria_for_Serotonin_Syndrome – Supplemental material for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques

Supplemental material, Appendix_1_Diagnostic_criteria_for_Serotonin_Syndrome for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques by Michael Ott, Julie K. Mannchen, Fariba Jamshidi and Ursula Werneke in Therapeutic Advances in Psychopharmacology

Supplemental Material

Appendix_2_Search_strategy-16Oct2018 – Supplemental material for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques

Supplemental material, Appendix_2_Search_strategy-16Oct2018 for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques by Michael Ott, Julie K. Mannchen, Fariba Jamshidi and Ursula Werneke in Therapeutic Advances in Psychopharmacology

Supplemental Material

Appendix_3_Laboratory_results – Supplemental material for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques

Supplemental material, Appendix_3_Laboratory_results for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques by Michael Ott, Julie K. Mannchen, Fariba Jamshidi and Ursula Werneke in Therapeutic Advances in Psychopharmacology

Supplemental Material

Appendix_4_Publications_included_FINAL – Supplemental material for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques

Supplemental material, Appendix_4_Publications_included_FINAL for Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques by Michael Ott, Julie K. Mannchen, Fariba Jamshidi and Ursula Werneke in Therapeutic Advances in Psychopharmacology

Footnotes

Appendix 4 Table A1.

Laboratory results.

	Unit	Result	Reference
Na⁺	mmol/l	142	137–145
K⁺	mmol/l	8.7	3.6–4.6
Creatinine	μmol/l	2188	45–90
Urea	mmol/l	64.9	3.1–7.9
Creatine kinase	μkat/l	2.94	<3.5
Troponin (high sensitive)	nmol/l	210	0–15
Myoglobin	μg/l	781	25–58
Phosphate	mmol/l	4.7	0.8–1.5
CRP	mg/l	28	<10
Arterial blood gas analysis
pH		7.09	7.35–7.45
pCO₂	kPa	2.6	4.6–6.0
Standard bicarbonate	mmol/l	5.2	22–27
Base excess	mmol/l	–22	±3
Urine analysis
Protein	g/l	3.1	<0.03

CRP, C-reactive protein.

Table A2:

Diagnostic criteria for Serotonin Syndrome.

	Sternbach 1991>3 of the following	Radomski 20004 major or 3 major and 2 minor		Hunter Serotonin ToxicityCriteria 2003
	Sternbach 1991>3 of the following	Major	Minor	Hunter Serotonin ToxicityCriteria 2003
Mental symptoms:		Semicoma/coma
	Mental status changes(confusion, hypomania)	Consciousnessimpairment
		Elevatedmood	Insomnia
	Agitation		Restlessness	Agitation¹
Neurological/neuromuscularsymptoms:	Myoclonus	Myoclonus
	Hyperreflexia	Hyperreflexia		Hyperreflexia⁴
		Rigidity		Hypertonicity/ rigidity⁵
				Spontaneous clonus
				Inducible clonus²
				Ocular clonus²
	Tremor	Tremor	Akathisia	Tremor³
	Incoordination		Uncoordination
	Shivering	Shivering
			Dilated pupils
Vegetativesymptoms:	Fever	Fever		Temperature > 38°C⁶
	Diaphoresis	Sweating
	Diarrhoea		Diarrhoea
			Tachycardia
			Hypertension/Hypotension
			Tachypnoea/dyspnoea
	● Addition or increase of a known serotonergic agent to an established medication regimen● Other etiologies have been ruled out● A neuroleptic had not been started or increased in dosage prior to the onset of the signs and symptoms listed above	1. Co-incidence with the addition or increase in a known serotonergic agent (to an established treatment regime)2. Clinical features described in the first criterion were not an integral part of the underlying psychiatric disorder prior to commencing the serotonergic agent.3. Other aetiologies (e.g. infectious, metabolic or endocrine, substance abuse or withdrawal) have been ruled out.4. A neuroleptic drug had not been started or increased in dosage prior to the onset of the signs and symptoms listed above		¹ in combination with diaphoresis .AND. [ocular .OR. inducable clonus]² in combination with [agitation .OR. diaphoresis]³ in combination with hyperreflexia⁴ in combination with tremor⁵ in combination with temperature > 38°C .AND. [ocular clonus .OR. inducible clonus]⁶ in combination with Hypertonicity/rigidity .AND. [ocular clonus .OR. inducible clonus]

Table A3.

Search strategy and method for case report analysis.

Objective	To identify pharmacological treatments to control arterial hypertension in the setting of serotonin syndrome
Eligibility criteria	Trials, observational studies or case reports in which participants fulfil the following criteria: Inclusion criteria: Patients (of any age) fulfilling one or more of the current three diagnostic criteria for serotonin syndrome [Sternbach criteria (SC), Radomski criteria (RC) or Hunter criteria (HC)]. Exclusion criteria: we excluded all cases: (1) not meeting any of the diagnostic criteria despite claiming a diagnosis of serotonin syndrome; (2) being aetiologically uncertain despite meeting the diagnostic criteria; (3) containing insufficient clinical information to rate; (4) being historical; or (5) implicating first-generation antipsychotics or concomitant neuroleptic malignant syndrome
Information sources (databases)	(1) MEDLINE(R) (2) ISI Web of Science: Science Citation Index Expanded (3) Cochrane Central Register of Controlled Trials CENTRAL, the Cochrane Library (4) CINAHL (5) TOXNET Toxline search (6) ClinicalTrials.gov (www.clinicaltrials.gov)
Search	Search was performed with the terms [‘serotonin syndrome’ OR ‘serotonin toxicity’] AND [‘hypertension’ OR ‘hypertensive’] Limits for case reports: from 2004, by which time the HC had been published and all three diagnostic criteria became available, until 31 December 2016
Study selection	Inclusion and exclusion criteria as above
Data collection process	Systematic review: we identified no studies meeting the inclusion criteria Case report analysis: we abstracted all eligible cases into a new dataset, including general patient characteristics, onset, clinical course, mode of presentation, symptoms, diagnostic criteria, associated medications, treatment and outcome; two investigators (UW and FJ or UW and MO) independently double rated all cases regarding the HC, SC or RC. If the article fulfilled the inclusion criteria, two authors then reviewed the full text of each article to extract data on medication, clinical data, treatment and outcome; disagreements between authors’ ratings were resolved by consensus
Data items	Symptoms of serotonin syndrome: 20 symptoms appearing in any of the three diagnostic criteria sets
	Blood pressure (BP) at presentation and highest/lowest BP reported.Pharmacologic treatment of arterial hypertension (substance) and time to normalizationDeath
Bias	As there were no trials or observational studies available, we relied on case reports onlyAt publication level: publication bias favouring unexpected or uncommon cases; as arterial hypertension is no criterion in Sternbach and Hunter classification, arterial hypertension may be underreportedAt study level: two investigators (UW and FJ or UW and MO) independently double rated all cases regarding HC, SC and RC, and reported BP
Summary measures	Time to normalization of BP after given treatment
Synthesis of results	Descriptive

Funding

This work was supported by a grant of the Norrbotten County Research & Development Fund, Sweden.

Conflict of interest statement

Ursula Werneke has received funding for educational activities (Masterclass Psychiatry Programme/EAPM 2016, Luleå, Sweden): Astra Zeneca, Janssen, Eli Lilly, Lundbeck, Novartis, Servier, Sunovion, Otsuka and Shire.

Michael Ott is a scientific advisory board member of Astra Zeneca Sweden.

Julie Mannchen and Fariba Jamshidi declare that there is no conflict of interest.

ORCID iD

Michael Ott

References

Boyer

. Serotonin syndrome (serotonin toxicity). Traub

Grayzel

, ed. Waltham, MA: UpToDate Inc. http://www.uptodate.com (2018, accessed 29 May 2018).

Buckley

Dawson

Isbister

GK.

Serotonin syndrome. BMJ 2014; 348: g1626.

Isbister

. Serotonin Syndrome. BMJ Best Practice. 2018. https://bestpractice.bmj.com/topics/en-gb/991 (accessed 15 May 2018).

Werneke

Jamshidi

Taylor

et al . Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases. BMC Neurol 2016; 16: 97.

Boyer

Shannon

The serotonin syndrome. N Engl J Med 2005; 352: 1112–1120.

Sternbach

The serotonin syndrome. Am J Psychiatry 1991; 148: 705–713.

Radomski

Dursun

Reveley

et al . An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55: 218–224.

Dunkley

Isbister

Sibbritt

et al . The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635–642.

Beatty

Nicholson

Langman

et al . Pharmacogenetic workup of perioperative serotonin syndrome. J Clin Anesth 2013; 25: 662–665.

10.

Bergeron

Boule

Perreault

Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 2005; 39: 956–961.

11.

Bosak

LoVecchio

Levine

Recurrent seizures and serotonin syndrome following “2C-I” ingestion. J Med Toxicol 2013; 9: 196–198.

12.

Brown

TM.

Nitroglycerin in the treatment of the serotonin syndrome. Am J Emerg Med 2004; 22: 510.

13.

Choudhury

Hote

Verma

Serotonin syndrome in a postoperative patient. J Anaesthesiol Clin Pharmacol 2011; 27: 233–235.

14.

Gnanadesigan

Espinoza

Smith

et al . Interaction of serotonergic antidepressants and opioid analgesics: is serotonin syndrome going undetected? J Am Med Dir Assoc 2005; 6: 265–269.

15.

Gollapudy

Kumar

Dhamee

MS.

A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. J Clin Anesth 2012; 24: 251–252.

16.

Inoue

Watanabe

Nodaira

et al . Peritoneal dialysis patient affected with serotonin syndrome. Nihon Naika Gakkai Zasshi 2008; 97: 3049–3051.

17.

Isenberg

Wong

Curtis

JA.

Serotonin syndrome triggered by a single dose of suboxone. Am J Emerg Med 2008; 26: 840 e3–e5.

18.

Levine

Truitt

O’Connor

AD.

Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose. J Med Toxicol 2011; 7: 312–316.

19.

Zhu

et al . Serotonin syndrome under combination of linezolid and low-dose citalopram with amiodarone. Psychiatry Clin Neurosci 2013; 67: 457.

20.

Miller

Lovell

EO.

Antibiotic-induced serotonin syndrome. J Emerg Med 2011; 40: 25–27.

21.

Monte

Chuang

Bodmer

Dextromethorphan, chlorphenamine and serotonin toxicity: case report and systematic literature review. Br J Clin Pharmacol 2010; 70: 794–798.

22.

Monte

Waksman

JC.

Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity. J Clin Psychopharmacol 2010; 30: 628–629.

23.

Monterrubio Villar

Cordoba Lopez

. Serotoninergic syndrome after the administration of clomipramine tablet in a critical patient. Med Intensiva 2007; 31: 343–344.

24.

Moseson

Nichols

The clinical roller coaster: severe serotonin syndrome. Crit Care Med 2013; 41.

25.

Ozkardesler

Gurpinar

Akan

et al . A possible perianesthetic serotonin syndrome related to intrathecal fentanyl. J Clin Anesth 2008; 20: 143–145.

26.

Rim

Gitlin

MJ.

Ziprasidone, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol 2010; 30: 470–471.

27.

Velez

Shepherd

Roth

et al . Serotonin syndrome with elevated paroxetine concentrations. Ann Pharmacother 2004; 38: 269–272.

28.

Wilson

Rooney

Baugh

et al . Recognition and management of perioperative serotonin syndrome. Am J Otolaryngol 2012; 33: 319–321.

29.

Young

Finn

Alvarez

et al . Serotonin syndrome: four report cases and review of the literature. An Med Interna 2008; 25: 125–130.

30.

Wilson

Rooney

Baugh

et al . Recognition and management of perioperative serotonin syndrome. Am J Otolaryngol 2012; 33: 319–321.

31.

Shah

Jain

AB.

Serotonin syndrome presenting as pulmonary edema. Indian J Pharmacol 2016; 48: 93–95.

32.

Magalhaes

Alves

Llerena

et al . Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. Drug Metabol Drug Interact 2014; 29: 129–141.

33.

Whirl-Carrillo

McDonagh

Hebert

et al . Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414–417.

34.

Rao

The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46: 281–290.

35.

Jaber

The serotonin syndrome complicating coprescription of paroxetine and clarithromycin. Am J Med 2006; 119.

36.

Lee

CD.

Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 1999; 19: 894–896.

37.

Pollak

Sketris

MacKenzie

et al . Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacother 1995; 29: 486–488.

38.

Halder

Muldoon

Ferrell

et al . Serotonin receptor 2A (HTR2A) gene polymorphisms are associated with blood pressure, central adiposity, and the metabolic syndrome. Metab Syndr Relat Disord 2007; 5: 323–330.

39.

Diaper

Rich

Wilson

et al . Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum Psychopharmacol 2013; 28: 562–575.

40.

Khurana

Baudendistel

TE.

Hypertensive crisis associated with venlafaxine. Am J Med 2003; 115: 676–677.

41.

Ramage

Villalon

CM.

5-hydroxytryptamine and cardiovascular regulation. Trends Pharmacol Sci 2008; 29: 472–481.

42.

Watts

SW.

5-HT in systemic hypertension: foe, friend or fantasy?

Clin Sci (Lond) 2005; 108: 399–412.

43.

Watts

Davis

RP.

5-hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther 2011; 29: 54–67.

44.

Sebekova

Raucinova

Dzurik

Serotonin metabolism in patients with decreased renal function. Nephron 1989; 53: 229–232.

45.

Berard

Sheehy

Zhao

et al . SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. Br J Clin Pharmacol 2017; 83: 1126–1133.

46.

Eddahibi

Chaouat

Morrell

et al . Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108: 1839–1844.

47.

Hooper

Delaney

Streeter

et al . Selective serotonin reuptake inhibitor exposure constricts the mouse ductus arteriosus in utero. Am J Physiol Heart Circ Physiol 2016; 311: H572–H581.

48.

Okoro

EO.

Overlap in the pharmacology of L-type Ca2+-channel blockers and 5-HT2 receptor antagonists in rat aorta. J Pharm Pharmacol 1999; 51: 953–957.

49.

el-Kashef

Hofman

Ehrhart

IC.

Verapamil inhibition of serotonin-induced vasoconstriction in dog lung. J Cardiovasc Pharmacol 1990; 15: 729–735.

50.

Shad

Saeed

SA.

The metabolism of serotonin in neuronal cells in culture and platelets. Exp Brain Res 2007; 183: 411–416.

51.

Sperti

Manasse

Kol

et al . Comparison of response to serotonin of radial artery grafts and internal mammary grafts to native coronary arteries and the effect of diltiazem. Am J Cardiol 1999; 83: 592–596, A8.

52.

Aslanian

Renaud

Changes in serotonin metabolism in the rat raphe magnus and cardiovascular modifications following systemic administration of clonidine and other central alpha 2-agonists: an in vivo voltammetry study. Neuropharmacology 1989; 28: 387–395.

53.

Agelink

Majewski

Andrich

et al . Short-term effects of intravenous benzodiazepines on autonomic neurocardiac regulation in humans: a comparison between midazolam, diazepam, and lorazepam. Crit Care Med 2002; 30: 997–1006.

54.

Colussi

Di Fabio

Catena

et al . Involvement of endothelium-dependent and -independent mechanisms in midazolam-induced vasodilation. Hypertens Res 2011; 34: 929–934.

55.

Huffman

Stern

TA.

The use of benzodiazepines in the treatment of chest pain: a review of the literature. J Emerg Med 2003; 25: 427–437.

56.

Marty

Gauzit

Lefevre

et al . Effects of diazepam and midazolam on baroreflex control of heart rate and on sympathetic activity in humans. Anesth Analg 1986; 65: 113–119.

57.

Roth

Driscol

. PDSP Ki Database. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. 2011, http://pdsp.med.unc.edu (accessed 18 August 2014).

58.

Berry

Maunder

Wilson

Carcinoid myopathy and treatment with cyproheptadine (Periactin). Gut 1974; 15: 34–38.

59.

Mills

KC.

Serotonin syndrome. A clinical update. Crit Care Clin 1997; 13: 763–783.

60.

Daunderer

Klinische Toxikologie. 140th ed. Landsberg am Lech, Germany: Ecomed, 1984.

61.

Kapur

Zipursky

Jones

et al . Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry 1997; 154: 884.

62.

Lidder

Ovaska

Archer

et al . Doctors’ knowledge of the appropriate use and route of administration of antidotes in the management of recreational drug toxicity. Emerg Med J 2008; 25: 820–823.

63.

Moertel

Kvols

Rubin

A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991; 67: 33–36.

64.

Robert

William

OR.

Handbook of Poisoning, 12th ed. Norwalk, CT: Appleton & Lange, 1987.

65.

Rüsch

Braun

Wulf

et al . Inhibition of human 5-HT(3A) and 5-HT(3AB) receptors by etomidate, propofol and pentobarbital. Eur J Pharmacol 2007; 573: 60–64.

66.

Yamanoue

Brum

Estafanous

FG.

Vasodilation and mechanism of action of propofol in porcine coronary artery. Anesthesiology 1994; 81: 443–451.

67.

Vasileiou

Xanthos

Koudouna

et al . Propofol: a review of its non-anaesthetic effects. Eur J Pharmacol 2009; 605: 1–8.

68.

Pensado

Molins

Alvarez

Effects of propofol on mean arterial pressure and systemic vascular resistance during cardiopulmonary bypass. Acta Anaesthesiol Scand 1993; 37: 498–501.

69.

Palaniyappan

Insole

Ferrier

Combining antidepressants: a review of evidence. Adv Psychiatric Treat 2009; 15: 90–99.

70.

Taylor

Paton

Kapur

Chapter 4: anxiety | depression. In: The Maudsley prescribing guidelines in psychiatry, 12th ed. Chichester: Wiley Blackwell 2015, pp. 231–352; page of quote, 256.

71.

Gonul

Akdeniz

Donat

et al . Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 889–891.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.43 MB

0.33 MB

0.34 MB

0.44 MB